Drug Analysis: Symbicort

  • ID: 4489118
  • Drug Pipelines
  • 27 pages
  • Datamonitor Healthcare
1 of 4
Drug Overview

AstraZeneca’s Symbicort ([budesonide + formoterol]) was the second inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) drug combination to launch on the respiratory market, starting with approval for asthma. This was followed by approval for chronic obstructive pulmonary disease in the EU in 2003 and in the US in February 2009. In Japan, where Symbicort is co-promoted by Astellas and AstraZeneca, the drug received approval in August 2012. Budesonide is an ICS that exhibits potent glucocorticoid activity, and formoterol is a LABA that acts locally in the lungs as a bronchodilator.
Note: Product cover images may vary from those shown
2 of 4
1 Product Profiles
  • Symbicort: Asthma
  • Symbicort: Chronic obstructive pulmonary disease (COPD)
List of Figures
Figure 1: Symbicort sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 2: Trelegy Ellipta for asthma - SWOT analysis
Figure 3: Symbicort sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 4: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Symbicort drug profile
Table 2: Symbicort pivotal trial data in asthma
Table 3: Symbicort late-phase trial data in asthma
Table 4: Symbicort sales for asthma in the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Symbicort drug profile
Table 6: Overview of pivotal trial data for Symbicort in COPD
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll